Skip to main content
Premium Trial:

Request an Annual Quote

Clondiag, CyBio to Launch Lab Diagnostics Instruments

NEW YORK, Feb. 2 (GenomeWeb News) - German bioarray firm Clondiag and CyBio will co-develop automatic pipetting and analyzing instruments for use in lab diagnostics, the companies announced today.


Aided by CyBio's resources, Clondiag will introduce its Clondiag ArrayStripProcessor, a package of 20 devices which it claims will eliminate user intervention in the pipetting, incubation, washing, selection, visualization, and data-management processes.


The product will be used for biochips with a 96-well microplate format. The first run of the new ASP package will be available in the second quarter.


Matthias Voigt, project manager for CyBio, told GenomeWeb News that his company has signed onto a 2-year agreement with Clondiag and has promised to deliver a minimum of 100 devices in that period for a fixed price.


He said Clondiag would market the new products to its customers in the biotechnology field.


Clondiag said in a statement that it aims to market the fully automated ASP to compliment the use of its biochip technology in molecular and immunological diagnostics, as well as genomic and serologic analytics.


Financial terms of the agreement were undisclosed. Both companies are based in Jena, Germany.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.